ETON Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of 20.83%. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Johnson & Johnson's return on equity of 34.46%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 67.32%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -4.12%. Given that Eton Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Eton Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Eton Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.322% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Johnson & Johnson's PE ratio is 21.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.81x versus 6.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Picard Medical has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Picard Medical's return on equity of --.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 67.32%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Eton Pharmaceuticals, Inc. has higher upside potential than Picard Medical, analysts believe Eton Pharmaceuticals, Inc. is more attractive than Picard Medical.

Eton Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.322% more volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Picard Medical quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Picard Medical's net income of --. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.81x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of --. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Sensei Biotherapeutics, Inc.'s return on equity of -68.55%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 67.32%. On the other hand Sensei Biotherapeutics, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 4.48%. Given that Eton Pharmaceuticals, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Eton Pharmaceuticals, Inc. is more attractive than Sensei Biotherapeutics, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.322% more volatile than S&P 500. In comparison Sensei Biotherapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sensei Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Sensei Biotherapeutics, Inc. quarterly revenues of --. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Sensei Biotherapeutics, Inc.'s net income of -$4.9M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Sensei Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.81x versus -- for Sensei Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology, Inc. has a net margin of -8.58% compared to Eton Pharmaceuticals, Inc.'s net margin of -67975.42%. Eton Pharmaceuticals, Inc.'s return on equity of -29.85% beat Vir Biotechnology, Inc.'s return on equity of -48.24%.

Eton Pharmaceuticals, Inc. has a consensus price target of $30.00, signalling upside risk potential of 67.32%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $16.56 which suggests that it could grow by 118.99%. Given that Vir Biotechnology, Inc. has higher upside potential than Eton Pharmaceuticals, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Eton Pharmaceuticals, Inc..

Eton Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.322% more volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.258%.

Eton Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.

Eton Pharmaceuticals, Inc. quarterly revenues are $22.5M, which are larger than Vir Biotechnology, Inc. quarterly revenues of $240K. Eton Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Vir Biotechnology, Inc.'s net income of -$163.1M. Notably, Eton Pharmaceuticals, Inc.'s price-to-earnings ratio is 92.00x while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals, Inc. is 6.81x versus 61.84x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.